UTI: uncomplicated vs complicated, treatment, and recurrent prevention — AU GP

What UTI actually is

Urinary tract infection (UTI) is a bacterial infection of any part of the urinary system — bladder (cystitis), kidneys (pyelonephritis), or prostate (prostatitis). It is one of the most common reasons for antibiotic prescribing in Australian general practice and one of the most frequently mismanaged: undertreating symptomatic infection risks renal involvement, while overtreating asymptomatic bacteriuria drives antimicrobial resistance without clinical benefit.

About 50% of women experience at least one UTI in their lifetime. Around 20% of women who have an initial UTI develop recurrent infections, defined as three or more episodes per year. Men experience UTI less often, but when it occurs it is always classified as complicated and warrants investigation.

The central stewardship principle shaping modern AU management: asymptomatic bacteriuria (ASB) — bacteria found on urine culture in a person without UTI symptoms — should not be treated with antibiotics in the vast majority of patients. Treating ASB in elderly, catheterised, or functionally impaired patients drives resistance and Clostridioides difficile infection without reducing symptomatic UTI rates or improving outcomes. The two exceptions are pregnancy and the period immediately before urological procedures.

A. Core clinical — the AU general practice framework

Uncomplicated versus complicated

eTG complete and the Australasian Society for Infectious Diseases (ASID) anchor UTI classification in the uncomplicated/complicated distinction — this determines antibiotic choice, course length, the need for culture, and whether further investigation is warranted.

Uncomplicated UTI — a healthy, non-pregnant adult woman with no structural or functional urinary tract abnormality and no immunocompromise. Cystitis (lower tract only). A clinical diagnosis is acceptable for typical presentations; culture is recommended but not always required before starting treatment in low-risk settings.

Complicated UTI — any of the following:

• Male sex — always complicated; investigate for structural or prostatic cause.
• Pregnancy — higher risk of ascending infection, pyelonephritis, preterm labour, and low birthweight even from lower-tract infection.
• Age under 2 years — fever without source, malodorous urine; always send culture; paediatric referral for first febrile UTI.
• Structural or functional abnormality — urinary catheter, renal calculi, neurogenic bladder, vesico-ureteric reflux, polycystic kidneys, transplanted kidney.
• Immunocompromise — poorly controlled diabetes, corticosteroid use, solid organ transplant, or immunosuppressive therapy.
• Healthcare-associated — recent hospitalisation or urological instrumentation.
• Upper tract involvement (pyelonephritis) — fever ≥38°C, loin pain, systemic features, rigors, or sepsis.

Common organisms

Per eTG, community-acquired UTI organisms in order of frequency:

• Escherichia coli — 70–85% of uncomplicated community UTI.
• Klebsiella pneumoniae, Proteus mirabilis, Enterobacter spp — approximately 10%.
• Staphylococcus saprophyticus — 5–15% in sexually active young women.
• Enterococcus faecalis — complicated and healthcare-associated settings.
• ESBL-producing organisms, Pseudomonas aeruginosa, MRSA — healthcare-associated or structural abnormality.
• Group B Streptococcus — pregnancy.

Trimethoprim resistance among community E. coli has reached approximately 25% in Australian samples. Where possible, guide treatment with culture results rather than prescribing purely empirically.

Symptoms and clinical presentation

Cystitis: dysuria, urinary frequency, urgency, suprapubic discomfort, cloudy or malodorous urine, haematuria (visible or microscopic), and urethral discomfort.

Pyelonephritis: the above cystitis symptoms plus fever (≥38°C), loin or costovertebral angle pain, nausea and vomiting, chills, or rigors. Sepsis features — altered mental state, hypotension, tachycardia — require emergency management immediately.

Atypical presentation in older adults: confusion, falls, or functional decline can accompany a UTI, but these alone do not establish the diagnosis — many elderly patients have incidental asymptomatic bacteriuria without UTI. Per ASID, antibiotic prescribing for non-specific symptoms with a positive dipstick or culture (without true UTI features) is a major driver of antimicrobial resistance in aged care.

Male presentation: urethritis (urethral discharge, dysuria — consider STI differential in younger men), acute prostatitis (perineal or rectal pain, fever, obstructive voiding symptoms). Always send urine culture.

Diagnosis

Per eTG and AMH:

Urinalysis dipstick — leucocyte esterase and nitrite have moderate sensitivity and specificity. Negative dipstick in a low-probability clinical context makes UTI unlikely. Positive dipstick plus typical symptoms supports clinical diagnosis in uncomplicated presentations. Dipstick alone is insufficient in: men, pregnant women, children, recurrent or atypical UTI, elderly patients, immunocompromised patients, suspected pyelonephritis, and treatment failures.

Mid-stream urine culture (MSU MCS) — the gold standard. Threshold ≥10⁵ colony-forming units/mL for typical pathogens (lower thresholds, e.g., 10² for S. saprophyticus, are clinically significant in symptomatic patients). Send for all complicated, recurrent, atypical, male, pregnant, paediatric, and treatment-failure UTI.

Bloods — FBE, U&E, CRP, and blood cultures for suspected pyelonephritis or sepsis.

Imaging — renal ultrasound for complicated, recurrent, atypical, first febrile UTI in children, or persistent haematuria. CT KUB for suspected renal calculi or abscess. Cystoscopy for recurrent UTI in men and persistent haematuria (bladder cancer pathway).

Differential to exclude: vaginitis and vulvovaginitis (discharge, itch — Candida, bacterial vaginosis, atrophic vaginitis); sexually transmitted infection (chlamydia, gonorrhoea, Mycoplasma genitalium) — especially in younger patients with dysuria and negative culture; interstitial cystitis or painful bladder syndrome (chronic pelvic pain without infection); bladder cancer (painless haematuria, persistent symptoms); renal calculi (colicky pain, haematuria, CT KUB).

B. Antibiotic selection — the evidence framework

Uncomplicated cystitis in non-pregnant adult women

Per eTG, three first-line agents with short-course evidence:

Agent	Dose	Duration	Notes
Trimethoprim	300 mg daily	3 days	First-line; resistance ~25% AU community E. coli — culture-guide where possible
Nitrofurantoin	100 mg QID	5 days	First-line; low resistance rates; avoid CrCl < 30 mL/min; avoid near term
Cefalexin	500 mg BD	5 days	Standard alternative; broader spectrum

Fosfomycin (Monurol) 3 g single dose — PBS Authority for ESBL-producing organism cystitis or when other agents are unsuitable. A convenient single-dose option for resistant or complicated-allergy presentations.

Avoid as first-line for uncomplicated cystitis: amoxicillin-clavulanate, ciprofloxacin, and ceftriaxone. These broad-spectrum agents are reserved for complicated or resistant infections. The TGA ciprofloxacin Boxed Warning — applicable to all fluoroquinolones — covers serious risks: tendinopathy and Achilles rupture, aortic aneurysm or dissection, peripheral neuropathy, dysglycaemia, and psychiatric adverse effects. Fluoroquinolones are not indicated for first-line uncomplicated cystitis per eTG.

Asymptomatic bacteriuria — do not treat in non-pregnant adults, elderly patients, catheterised patients, or patients with nonspecific symptoms. Treat only in pregnancy and immediately before urological procedures per ASID.

Pyelonephritis

Mild to moderate, outpatient-eligible (tolerating oral intake, not septic):

• Amoxicillin-clavulanate 875/125 mg BD × 14 days
• Cefalexin 500 mg QID × 14 days
• Trimethoprim-sulfamethoxazole 160/800 mg BD × 14 days (if susceptible per MCS)

Severe or inpatient:

• IV gentamicin + ampicillin, or IV ceftriaxone, or piperacillin-tazobactam for sepsis features.
• Switch to oral antibiotics when clinically responsive (typically 48–72 hours). Total course 14 days.
• CT KUB or renal ultrasound for atypical, treatment failure, male, or suspected obstruction and abscess.

Male UTI and prostatitis

Male UTI is always complicated per USANZ and eTG. Use a 7–14 day course for cystitis; the longer end applies when prostatitis cannot be excluded.

Acute bacterial prostatitis: trimethoprim-sulfamethoxazole 160/800 mg BD × 4 weeks, or ciprofloxacin 500 mg BD × 4 weeks (noting the Boxed Warning — reserve for susceptible organism confirmed by culture). Fluoroquinolone achieves excellent prostate tissue penetration, which is why it is preferred when appropriate. Urology or specialist input for severe or recurrent prostatitis.

Chronic bacterial prostatitis: 4–6 weeks of fluoroquinolone or trimethoprim-sulfamethoxazole. USANZ guidelines and specialist review guide long-term management.

Catheter-associated UTI (CAUTI)

Per NHMRC infection control guidelines and ASID: treat only if symptomatic (fever, suprapubic or loin pain, sepsis, or new-onset delirium without another cause). Change the catheter simultaneously when treating. Do not use prophylactic antibiotics in patients with indwelling catheters. Empirical therapy is based on local resistance patterns — often piperacillin-tazobactam or ceftriaxone while awaiting culture.

C. Recurrent UTI — prevention-first strategies

Recurrent UTI in women (≥3 episodes/year, or ≥2 in 6 months) warrants a structured prevention approach that begins with non-antibiotic strategies. ASID and eTG explicitly recommend non-antibiotic measures as the first step before continuous antibiotic prophylaxis — the stewardship rationale is compelling: prophylactic antibiotics select for resistance and cause candidiasis and C. diff infection.

Non-antibiotic prevention

Methenamine hippurate (Hiprex) 1 g BD — a urinary antiseptic that releases formaldehyde locally in acidic urine, inhibiting bacterial growth without systemic antibiotic activity. The ALTAR trial (Harding et al., BMJ 2022) — a UK multicentre randomised controlled trial with 240 women with recurrent UTI followed over 12 months — demonstrated non-inferiority to antibiotic prophylaxis on UTI rate, antibiotic consumption, and quality of life. Available over the counter in Australia. Less effective in alkaline urine; consistent twice-daily dosing is necessary.

Topical vaginal oestrogen (postmenopausal women) — strong evidence for restoring the vaginal and periurethral microbiome, reducing colonisation by uropathogenic bacteria, and substantially decreasing UTI recurrence. eTG recommends this as first-line prevention in postmenopausal women. PBS general benefit options: estriol cream (Ovestin) applied 1–2 times weekly, vaginal oestrogen tablets (Vagifem 10 mcg), or Estring vaginal ring. Systemic oestrogen absorption at these doses is negligible — this is not equivalent to systemic HRT and does not carry the same contraindication profile.

Cranberry products — A-type proanthocyanidins inhibit E. coli type-1 and P fimbriae adhesion to the urothelium. Cochrane systematic reviews find a modest but consistent reduction in symptomatic UTI in women with recurrent infections. Use quality-controlled products specifying proanthocyanidin content. Not effective for treating established infection.

D-mannose 2 g daily — competes with E. coli fimbriae binding sites in the bladder wall. Emerging RCT evidence supports a modest preventive effect; less robust than methenamine or vaginal oestrogen, but safe and reasonable as an adjunct.

Hydration — 2–2.5 litres fluid daily; dilutes uropathogens and promotes regular bladder emptying. Modest evidence base; low-risk lifestyle advice.

Behavioural measures — post-coital voiding has modest historical support. Avoiding spermicide use reduces periurethral E. coli colonisation in some women. Reviewing bath additives and hygiene products is worthwhile.

Antibiotic prophylaxis (after non-antibiotic trial fails)

When non-antibiotic strategies are insufficient after an adequate trial, eTG supports:

• Daily low-dose nocturnal: trimethoprim 150 mg, or nitrofurantoin 50 mg, or cefalexin 250 mg.
• Post-coital single dose: trimethoprim 150 mg or nitrofurantoin 50 mg after intercourse (for coitally linked pattern).
• Patient-initiated self-start: patient-held prescription for self-start on symptom onset in established recurrent UTI with reliable symptom recognition.

Review prophylaxis at 6 months; taper or cease where possible. Resist indefinite continuation without periodic reassessment.

D. Australian operations

PBS-listed antibiotics

Per PBS and AMH:

• Trimethoprim 300 mg tablets — PBS general benefit.
• Nitrofurantoin 50/100 mg capsules (Macrobid sustained-release; Macrodantin) — PBS general benefit.
• Cefalexin 250/500 mg capsules — PBS general benefit.
• Amoxicillin-clavulanate 875/125 mg tablets — PBS general benefit.
• Trimethoprim-sulfamethoxazole (Bactrim DS) 160/800 mg — PBS general benefit; caution in G6PD deficiency.
• Ciprofloxacin 500 mg — PBS Authority Required (streamlined) for specific or resistant indications; TGA Boxed Warning.
• Fosfomycin (Monurol) 3 g sachet — PBS Authority for ESBL-producing organism cystitis or when other oral agents are unsuitable.

MBS item numbers

Per MBS Online:

• Standard consultations — items 23, 36, 44.
• GPCCMP (GP Chronic Condition Management Plan) — items 965/967 (replaced items 721/723/732 from 1 July 2025); applicable for recurrent or complicated UTI with comorbid conditions.
• Aboriginal and Torres Strait Islander Health Assessment — item 715.
• 75+ Health Assessment — item 707.
• MSU MCS — standard Medicare-rebatable pathology.
• Renal ultrasound — Medicare-rebatable for complicated, recurrent, structural, or haematuria workup.
• CT KUB — Medicare-rebatable for suspected calculi or atypical presentation.

Antimicrobial stewardship

NPS MedicineWise and state antimicrobial stewardship programs promote: culture-guided prescribing, avoiding broad-spectrum agents for uncomplicated cystitis, not treating asymptomatic bacteriuria, completing prescribed courses without sharing antibiotics, and reviewing antibiotic prophylaxis every 6 months.

E. Special populations

Pregnancy. Send MSU MCS for all pregnant women — asymptomatic bacteriuria is always treated in pregnancy (unlike the non-pregnant rule) because of the risk of ascending pyelonephritis, preterm labour, and low birthweight. eTG recommended agents: cefalexin 500 mg BD × 5 days, or nitrofurantoin 100 mg QID × 5 days (avoid near term — neonatal haemolytic anaemia risk, especially G6PD). Avoid in pregnancy: trimethoprim in first trimester (folate antagonism — neural tube defect risk; may be used after 12 weeks if no alternative is suitable), fluoroquinolones (animal cartilage toxicity data), tetracyclines (fetal teeth and bone), sulfonamides in third trimester (kernicterus risk). Pyelonephritis in pregnancy: admit to hospital; IV ceftriaxone or ampicillin with gentamicin (short-course gentamicin is acceptable in pregnancy); step down to oral when clinically responsive.

Children. Always send MSU MCS. Under 3 months: admit, IV antibiotics, renal ultrasound, paediatrics referral. Over 3 months and not septic: outpatient trimethoprim-sulfamethoxazole or cefalexin × 5 days weight-adjusted. First febrile UTI at any age: renal ultrasound to detect vesico-ureteric reflux or structural anomaly; paediatrics referral. eTG paediatric UTI guidelines provide full dosing and investigation guidance.

Older adults. A positive dipstick or urine culture in an elderly patient with confusion or functional decline does not establish UTI — the majority of these presentations involve incidental asymptomatic bacteriuria, not true infection. True UTI in an older adult requires UTI-specific symptoms (dysuria, frequency, suprapubic pain, or fever with haematuria or loin pain) alongside bacteriuria. Per ASID, reflexive antibiotic treatment of non-specific symptoms with incidental bacteriuria is a major source of antimicrobial resistance in aged care settings.

Immunocompromised. Lower threshold to culture-guided treatment; urology specialist input for recurrent or complicated infections in solid organ transplant recipients, people on immunosuppression, or those with structural renal abnormalities.

Catheterised patients (CAUTI). Treat only symptomatic infection. Change the catheter simultaneously with treatment. Avoid prophylactic antibiotics in indwelling catheter. Continence Foundation of Australia provides patient resources on catheter care.

When to escalate

Refer or escalate when:

• Pyelonephritis with sepsis features — emergency department and IV antibiotics immediately; 000 if shocked.
• Suspected obstructive uropathy (renal calculi, tumour) — emergency department and urology.
• Any UTI in a male patient — urology workup including renal ultrasound; cystoscopy for recurrent episodes.
• Persistent haematuria after resolution of infection — urology bladder cancer pathway (cystoscopy, CT IVP or CT KUB).
• Recurrent UTI in a postmenopausal woman despite topical vaginal oestrogen and methenamine hippurate — urology or urogynaecology specialist.
• Suspected emphysematous pyelonephritis in a person with diabetes — emergency.
• Treatment failure after empirical antibiotic — send MSU MCS, reassess diagnosis (interstitial cystitis, vaginitis, STI, bladder or renal pathology).
• First febrile UTI in a child — paediatrics referral and renal ultrasound as first step.
• Suspected renal or perinephric abscess — imaging and urology for drainage.

What this article is and is not

This is general health information drawn from current Australian general practice guidelines — Therapeutic Guidelines (eTG), Australian Medicines Handbook (AMH), ASID Antimicrobial Stewardship Guidelines, USANZ, and NHMRC infection control guidelines — and the ALTAR 2022 randomised trial and Cochrane evidence on cranberry products. It is not personal medical advice and does not create a doctor–patient relationship. Antibiotic choice, investigation, and referral decisions are made with your own GP and treating clinicians based on your culture results, clinical picture, renal function, and pregnancy status.

For Australian consumer-friendly resources: HealthDirect — UTI, Better Health Channel — UTI, Continence Foundation of Australia.

---

Sources cited

1. Therapeutic Guidelines (eTG) — Antibiotic: UTI / Pyelonephritis / Prostatitis
2. Australian Medicines Handbook (AMH)
3. ASID Antimicrobial Stewardship Guidelines
4. USANZ — Urological Society of Australia and New Zealand
5. ALTAR trial — Harding et al., BMJ 2022
6. NHMRC — Australian Guidelines for Prevention and Control of Infection in Healthcare 2019
7. Cochrane Library — Cranberries for preventing urinary tract infections
8. HealthDirect — UTI
9. Better Health Channel — UTI
10. NPS MedicineWise — Antibiotic stewardship
11. MBS Online
12. TGA — Ciprofloxacin and fluoroquinolone safety information
13. Continence Foundation of Australia
14. PBS — Antimicrobials listed for UTI